|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.1 USD | -3.51% |
|
-8.33% | -81.20% |
| 05-14 | Maxim Downgrades Augmedix to Hold From Buy | MT |
| 05-14 | B. Riley Adjusts Price Target on Augmedix to $3 From $5.50, Keeps Buy Rating | MT |
Augmedix, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 13.47 million compared to USD 9.63 million a year ago. Net loss was USD 6.5 million compared to USD 5.24 million a year ago.
Basic loss per share from continuing operations was USD 0.12 compared to USD 0.14 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -81.20% | 55.56M | |
| +11.23% | 69.28B | |
| +5.94% | 17.59B | |
| +12.95% | 13.99B | |
| +22.34% | 13.78B | |
| +15.50% | 10.35B | |
| -21.01% | 7.17B | |
| -4.24% | 6.03B | |
| +0.93% | 5.23B | |
| -2.01% | 5.03B |
AUGMEDIX, INC. 
